Medical News

Predictors of Mortality Rate Among Adult HIV-positive Patien...
AIDS Res. Ther.

The incidence of death was high. Being male, viral load, those with advanced STAGE (III & IV), TB co-infected,...

10 May 2021

Integrase Inhibitors Versus Efavirenz Combination Antiretrov...
AIDS Res. Ther.

This meta-analysis demonstrates similar efficacy and safety of INIs-based ART compared with EFV-based ART. This...

05 May 2021

Virologic Outcomes of Switching to Dolutegravir Functional M...
AIDS Res.Ther.

In this real-world cohort, the majority of whom had virus with the M184V/I and ≥ 1 additional NA mutation,...

04 May 2021

A Randomized Controlled Trial Evaluating Combination Detecti...
JIAS

Combining three distinct HIV testing and referral strategies increased the detection of previously undiagnosed HIV...

03 May 2021

Key Trials

Benefits of Inhaled Budesonide in Early COVID-19 Infection: STOIC Study

This infographic summarises the key points of the STOIC study and outlines the benefits of administering inhaled budesonide in early COVID-19...

48-week Efficacy and Safety of Switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide in Virologically Suppressed People Living with HIV aged > 65 years

The presents study evaluated efficacy and safety of switching older people with HIV to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)....

Efficacy of Reduced Doses of both TDF and EFV for the Treatment of HIV-1 Infection

This study is the first randomized, controlled trial in an antiretroviral-naive population that evaluated the efficacy of reduced doses of both...

144-week Efficacy and Safety of Fixed-dose Combination Bictegravir, Emtricitabine, and Tenofovir alafenamide versus Dolutegravir-containing Regimens for Initial Treatment of HIV-1 Infection

This is a randomised, double-blind, multicentre, phase 3 trial evaluating 144-week efficacy and safety of fixed-dose combination bictegravir,...

Our Publications

Antiretroviral-based Prevention Strategies in HIV

Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...

Antiretroviral Therapy – Current Recommendations

Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....

Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets

Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...

Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets

Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...

Patient Education

Live Healthier, Live Longer

This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment....

Living with Hope

This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects. ...

Slide Library

HIV - HCV Coinfection

This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...

 
Email this page
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use

PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...

 
Email this page
HIV- Post-exposure Prophylaxis (PEP)

Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...

 
Email this page
Isoniazid Preventive Therapy in HIV Infection

HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....

 
Email this page

Poll

Which is your preferred 3rd drug in a first-line regimen?

Efavirenz 600
50% (3 votes)
Efavirenz 400
17% (1 vote)
Dolutegravir
33% (2 votes)
Total votes: 6